-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, VBI Vaccines announced that the second phase 2a/2b clinical trial of VBI-2601 (BRII-179), a novel recombinant protein immunotherapy jointly developed with Brii Biosciences, has completed the first patient dosing
Hepatitis B is one of the most significant infectious disease threats in the world, with more than 290 million people infected globally
VBI-2601 is an innovative recombinant protein-based immunotherapy designed to enhance B- and T-cell immune responses based on a VBI-based prophylactic HBV vaccine candidate
Phase 2a of this randomized, double-blind, placebo-controlled Phase 2a/2b clinical trial is expected to enroll 120 patients, with the primary endpoint being the percentage of patients with HBsAg clearance at the end of treatment; 480 patients will be re-enrolled in Phase 2b, the primary endpoint Percentage of patients who achieved functional cure (defined as undetectable HBsAg and observed sustained suppression of HBV DNA)
References:
[1] VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio.
https:// part-of-expansion-of-clinical-collaboration-with-brii-bio/
(Original abridged)
